» Articles » PMID: 33602140

Partial Regression of Foveoschisis Following Vitamin B6 Supplementary Therapy for Gyrate Atrophy in a Chinese Girl

Overview
Journal BMC Ophthalmol
Publisher Biomed Central
Specialty Ophthalmology
Date 2021 Feb 19
PMID 33602140
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To report a case of genetically confirmed gyrate atrophy (GA) of choroid and retina, who showed partial regression of foveoschisis following vitamin B6 supplementary therapy.

Case Presentation: A 6-year-old Chinese girl complained about night blindness and progressive decreased vision in both eyes. Her best corrected visual acuity (BCVA) was 20/63 OD and 20/100 OS. Fundus examination showed bilateral multiple, sharply demarcated, scallop-shaped chorioretinal atrophy areas in the midperipheral and peripheral of the fundus. Spectral domain optical coherence tomography (SD-OCT) showed increased central macular thickness (CMT) with multiple intraretinal cystic spaces in the both eyes. There was no leakage or staining in the macular area in late phase of fluorescein angiography (FA). Blood tests confirmed hyperornithinemia and genetic analysis revealed two heterozygous mutations on ornithine aminotransferase (OAT) gene. Based on clinical presentation and genetic test, the patient was diagnosed as GA of the choroid and retina and further treated with vitamin B6 supplementary for three weeks. Her serum ornithine levels did not change but CMT on SD-OCT declined with partial regression of intraretinal cystic spaces. Then, the patient discontinued the drug because of severe muscle pain, and foveoschisis increased to initial level a month later.

Conclusions: Foveoschisis is a rare complication of GA. Vitamin B6 supplementation may alleviate foveoschisis, but its effort for reducing serum ornithine level might be limited. Potential drug adverse effects should be noted in pediatric patients.

Citing Articles

Biochemical Studies on Human Ornithine Aminotransferase Support a Cell-Based Enzyme Replacement Therapy in the Gyrate Atrophy of the Choroid and Retina.

Pampalone G, Chiasserini D, Pierige F, Camaioni E, Orvietani P, Bregalda A Int J Mol Sci. 2024; 25(14).

PMID: 39063173 PMC: 11277095. DOI: 10.3390/ijms25147931.


Three siblings with gyrate atrophy of the choroid and retina: a case report.

Rym M, Molka F, Amel B, Sameh H, Monia C Int J Ophthalmol. 2023; 16(12):2133-2135.

PMID: 38111946 PMC: 10700090. DOI: 10.18240/ijo.2023.12.28.

References
1.
Wan R, Chang A . Optic disc pit maculopathy: a review of diagnosis and treatment. Clin Exp Optom. 2019; 103(4):425-429. DOI: 10.1111/cxo.12957. View

2.
Tripathy K, Chawla R, Sharma Y, Gogia V . Ultrawide field fluorescein angiogram in a family with gyrate atrophy and foveoschisis. Oman J Ophthalmol. 2016; 9(2):104-6. PMC: 4932791. DOI: 10.4103/0974-620X.184529. View

3.
Zhioua Braham I, Ammous I, Maalej R, Boukari M, Boussen I, Errais K . Multimodal imaging of foveoschisis and macular pseudohole associated with gyrate atrophy: a family report. BMC Ophthalmol. 2018; 18(1):89. PMC: 5897997. DOI: 10.1186/s12886-018-0755-9. View

4.
Feldman R, Mayo S, Robertson D, Jones J, Rostvold J . Epiretinal membranes and cystoid macular edema in gyrate atrophy of the choroid and retina. Retina. 1989; 9(2):139-42. DOI: 10.1097/00006982-198909020-00014. View

5.
GASS J . Nicotinic acid maculopathy. Am J Ophthalmol. 1973; 76(4):500-10. DOI: 10.1016/0002-9394(73)90738-1. View